-
Mashup Score: 14Tumor and Peritoneum-Associated Macrophage Gene Signature as a Novel Molecular Biomarker in Gastric Cancer - 15 day(s) ago
A spectrum of immune states resulting from tumor resident macrophages and T-lymphocytes in the solid tumor microenvironment correlates with patient outcomes. We hypothesized that in gastric cancer (GC), macrophages in a polarized immunosuppressive transcriptional state would be prognostic of poor survival. We derived transcriptomic signatures for M2 (M2TS, MRC1; MS4A4A; CD36; CCL13; CCL18; CCL23; SLC38A6; FGL2; FN1; MAF) and M1 (M1TS, CCR7; IL2RA; CXCL11; CCL19; CXCL10; PLA1A; PTX3) macrophages, and cytolytic T-lymphocytes (CTLTS, GZMA; GZMB; GZMH; GZMM; PRF1). Primary GC in a TCGA stomach cancer dataset was evaluated for signature expressions, and a log-rank test determined overall survival (OS) and the disease-free interval (DFI). In 341 TCGA GC entries, high M2TS expression was associated with histological types and later stages. Low M2TS expression was associated with significantly better 5-year OS and DFI. We validated M2TS in prospectively collected peritoneal fluid of a GC patie
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1 - 1 month(s) ago
Abstract. Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D-CDK4/6, driving proliferation and resistance to hormonal manipulation in prostate cancer. This study was designed to detect signals of clinical activity for abemaciclib in treatment-refractory metastatic castration‐resistant prostate cancer (mCRPC). Methods: Eligible patients had progressive mCRPC, measurable disease, and previously received ≥1 novel hormonal agent(s) and 2 lines of taxane chemotherapy. Abemaciclib 200 mg BID was administered on a continuous dosing schedule. Primary endpoint was objective response rate (ORR) without concurrent bone progression. This study was designed to detect a minimum ORR of 12.5%. Results : At trial entry, forty (90.9%) of 44 patients had objective radiographic disease progression, four (9.1%) had prostate-specific antigen (
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Terrific paper from @neerajaiims @cdanicas et al in @CCR_AACR re: #abemaciclib in #metastatic #prostatecancer ... full article here: https://t.co/K4EjuL4Jm6 https://t.co/j2zmtRFfwZ
-
-
Mashup Score: 6MOASC 2024 Oncology Summit Archives - 1 month(s) ago
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing … … At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical … … Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T. … … The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of … …
Source: oncologytube.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncologytube: VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://t.co/Pvp9JhYM98 featuring presentatio…
-
-
Mashup Score: 6MOASC 2024 Oncology Summit Archives - 1 month(s) ago
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing … … At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical … … Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T. … … The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of … …
Source: oncologytube.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncologytube: VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://t.co/Pvp9JhYM98 featuring presentatio…
-
-
Mashup Score: 3Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease - 2 month(s) ago
Nature Microbiology – Graft-versus-host disease, a T cell-driven inflammatory condition, is associated with altered microbial bile acid metabolism in both mice and humans and this is linked to…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Terrific paper from @DrSarahLindner @Orianamilt #ClarissaCampbell @DrMvandenBrink showing the link between #microbial processing of bile acids & immunity. @NatureMicrobiol @cityofhope @MSKCancerCenter https://t.co/opORgPB1WE
-
-
Mashup Score: 1Hoarseness and Wheezing in Patient With Arrhythmia - 2 month(s) ago
She first noticed crackling of her voice, which was worse when she laughed.
Source: reference.medscape.comCategories: General Medicine News, Hem/OncsTweet-
RT @AlexisLevee: Check out our Case Challenge on @Medscape! @jmortimer @schmolze Link: https://t.co/Ma626rvpvP Can you guess the diagnosi…
-
-
Mashup Score: 4Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial - 3 month(s) ago
Nature Medicine – In the final report of a phase 1/2 trial evaluating allogeneic CD19-specific CAR-NK cells armored with IL-15 in patients with CD19+ hematologic malignancies, the therapy was shown…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @SaheliSadanand: ICYMI -- results of this trial in @NatureMedicine! https://t.co/bVtMEgYBFE
-
-
Mashup Score: 2Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats - Nature - 6 month(s) ago
Epstein–Barr Virus (EBV) nuclear antigen 1 is shown to induce breakage of a fragile site on chromosome 11 by binding to a cluster of EBV-like imperfect palindromic repeats.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Huge talent in this symposium. @JuliaszLi @UCSDCancer @UCSDHealth @DamonRunyon highlights her work on the contribution of #EBV to chromosomal instability in @Nature https://t.co/ixaur6Z0UK https://t.co/MuPk5hEFsf
-
-
Mashup Score: 6
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm
Source: www.fda.govCategories: Latest Headlines, UrologyTweet-
RT @DipeshUpretyMD: FDA approves perioperative Pembrolizumab for resectable NSCLC #LCSM @OncoAlert @BTFCancerNews https://t.co/3rIvj61VMk
-
-
Mashup Score: 11The OncoAlert Newsletter is NOW OUT Click to Register - 8 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Latest Headlines, UrologyTweet-
RT @OncoAlert: The @oncoAlert 🚨ROUND UP IS OUT‼️ Aug 25-31st, 2023 REGISTER FOR THE NEWSLETTER AT: https://t.co/yzt83gqQkF 📨 Discussing: ✅…
-
Nice paper from @Yanghee61217641's group at @cityofhope defining a tumor/peritoneum-associated macrophage gene signature associated with outcome in #gastriccancer - full paper in @IJMS_MDPI here: https://t.co/LJlU0a0AMt https://t.co/3c6ced5Jd3